IDEXX Laboratories, Inc. IDXX
702.37 USD +30.33 (+4.51%)
Nov 4, 2026, 3:43 PM EST
681.70 Day range 713.74
504.70 52-week range 766.68
- YTD
- +3.82%
- 1 year
- -2.73%
News
benzinga.com Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $810 Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $805 to $810.
benzinga.com UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $700 UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $627 to $700.
zacks.com Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 200-day moving average, and this…
247wallst.com IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session…
seekingalpha.com IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript
benzinga.com Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
benzinga.com Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock rose Monday after the company reported better-than-expected third-quarter results and raised 2026 guidance, driven by expansion of diagnostic utilization,…
benzinga.com Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic IDEXX tops Q3 estimates and lifts 2026 guidance as rising test intensity and global instrument sales offset softer U.S. veterinary clinic traffic.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
reuters.com IDEXX raises forecast, betting diagnostics can offset weak vet visits IDEXX raises forecast, betting diagnostics can offset weak vet visits
fool.com IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction IDEXX grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets. The higher 2026 profit forecast doesn't come from testing demand.
marketbeat.com IDEXX Laboratories Q3 Earnings Call Highlights IDEXX Laboratories NASDAQ: IDXX reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising…
benzinga.com If You Invested $100 In IDEXX Laboratories Stock 15 Years Ago, You Would Have This Much Today IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 15 years by 8.26% on an annualized basis producing an average annual return of 20.91%. Currently, IDEXX Laboratories has a…
zacks.com Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
zacks.com IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market IDEXX Laboratories beats Q3 2026 earnings and revenue estimates as diagnostic demand boosts growth and margins expand, prompting higher 2026 revenue and earnings guidance.
benzinga.com IDEXX Laboratories, Perion Network, TAT Technologies And Other Big Stocks Moving Higher On Monday U.S. stocks were higher, with the Dow Jones gaining around 500 points on Monday.
benzinga.com IDEXX Laboratories, Perion Network, TAT Technologies And Other Big Stocks Moving Higher On Monday U.S. stocks rose as IDEXX jumped 20.1% on strong results and raised guidance; Perion, TAT Technologies and airlines also gained.
benzinga.com IDEXX Laboratories Q3 2026 Earnings Call Transcript IDEXX Laboratories (NASDAQ:IDXX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
zacks.com Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $3.98 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to earnings of $3.4 per share a year ago.
benzinga.com IDEXX Laboratories Q3 EPS $4.01 Beats $3.71 Estimate, Sales $1.214B Beat $1.191B Estimate IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.01 per share which beat the analyst consensus estimate of $3.71 by 8.09 percent. This is a 17.94 percent increase over earnings of…
benzinga.com IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.69-$14.94 to $14.96-$15.16 vs $14.82 Est; Raises FY2026 Sales Guidance from $4.700B-$4.745B to $4.741B-$4.767B vs $4.723B Est IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.69-$14.94 to $14.96-$15.16 vs $14.82 analyst estimate. Raises FY2026 sales outlook from $4.700 billion-$4.745 billion to…
businesswire.com IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
zacks.com Gear Up for Idexx (IDXX) Q3 Earnings: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Idexx (IDXX) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for…
benzinga.com UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $627 UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $670 to $627.
defenseworld.net IDEXX Laboratories, Inc. $IDXX Shares Purchased by Citizens Financial Group Inc. RI Citizens Financial Group Inc. RI grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 51.1% in the third quarter, according to the company in its most recent 13F filing with the…
zacks.com Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
defenseworld.net IDEXX Laboratories, Inc. $IDXX Shares Acquired by Diversify Advisory Services LLC Diversify Advisory Services LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 39.7% during the third quarter, according to the company in its most recent disclosure with…
zacks.com Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.- benzinga.com JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $750 JP Morgan analyst Chris Schott maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $775 to $750.
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.- benzinga.com Keybanc Initiates Coverage On IDEXX Laboratories with Sector Weight Rating Keybanc analyst Steve Dechert initiates coverage on IDEXX Laboratories (NASDAQ:IDXX) with a Sector Weight rating.
benzinga.com Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
benzinga.com Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710 Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.- benzinga.com UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670 UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.
benzinga.com Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670 Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.
benzinga.com Why Is IDEXX Laboratories Stock Gaining Tuesday? IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.
benzinga.com IDEXX Laboratories Q2 2026 Earnings Call Transcript IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
benzinga.com IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to…- benzinga.com IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of…
- benzinga.com UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620 UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.
benzinga.com Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years 
benzinga.com Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency Idexx Laboratories shares edge higher as revenue tops estimates but earnings per share misses; guidance raised.
benzinga.com Transcript: IDEXX Laboratories Q1 2026 Earnings Conference Call - benzinga.com CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $3.47 per share which beat the analyst consensus estimate of $3.41 by 1.76 percent. This is a 20.91 percent increase over earnings of…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.29-$14.80 to $14.45-$14.90 vs $14.53 Est; Raises FY2026 Sales Guidance from $4.632B-$4.720B to $4.675B-$4.760B vs $4.678B Est IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.29-$14.80 to $14.45-$14.90 vs $14.53 analyst estimate. Raises FY2026 sales outlook from $4.632 billion-$4.720 billion to…
- benzinga.com UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $640 UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $730 to $640.
- benzinga.com Citigroup Initiates Coverage On IDEXX Laboratories with Neutral Rating, Announces Price Target of $650 Citigroup analyst Daniel Grosslight initiates coverage on IDEXX Laboratories (NASDAQ:IDXX) with a Neutral rating and announces Price Target of $650.